Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Magrabi Hospital - Doha | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Group II (Ketamine group). Where patients will receive ketamine in a dose of 0.3 mg/kg in physiological solution.
Group III (Dexmedetomidine group). where patients will receive dexmedetomidine in a dose of 0.5 ug/kg in a physiological solution.
-Primary outcome will be the incidence of POCD, the secondary outcomes will be the hemodynamic changes and the changes in the intraocular pressure.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group I (Control group) | Placebo Comparator | - The patients in this group will receive normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study. |
|
| Group II (Ketamine group) | Experimental | - The patients in this group will receive ketamine at a dose of 0.3 mg/kg dissolved in normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study. |
|
| Group III (Dexmedetomidine group) | Experimental | - The patients in this group will receive Dexmedetomidine in a dose of 0.5 ug/kg dissolved in normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ketamine | Drug | Ketamine at a dose of 0.3 mg/kg dissolved in normal saline. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| The postoperative cognitive function | Short Portable Mental Status Questionnaire (SPMSQ) It is a score system that depends upon the number of errors in 10 questions asked to the patient where; - 0-2 errors: normal mental functioning 3-4 errors: mild cognitive impairment 5-7 errors: moderate cognitive impairment 8 or more errors: severe cognitive impairment Mental Status Questionnaire (SPMSQ) score will be used to assess the cognitive dysfunction | Within the first 3 days after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Change in the intraocular pressure | The IOP will be measured before the peribulbar anesthesia, min, 5 min and 10 min after peribulbar injection, then immediately after surgery. | Throughout the whole intraoperative period |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mohamed Oreby, M.D | Tanta University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Faculty of Medicine | Tanta | Algharbia Governate | 31511 | Egypt |
The data of the primary outcome will be available with the corresponding author till 6 months after approval of the publication of the trial.
till 6 months after approval of the publication of the trial.
Contact the principle investigator
Not provided
Not provided
| ID | Term |
|---|---|
| D000079690 | Postoperative Cognitive Complications |
| D002386 | Cataract |
| D060825 | Cognitive Dysfunction |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D003072 | Cognition Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D007649 | Ketamine |
| D020927 | Dexmedetomidine |
| D000077330 | Saline Solution |
| ID | Term |
|---|---|
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
| Dexmedetomidine |
| Drug |
Dexmedetomidine at a dose of 0.5 ug/kg dissolved in normal saline. |
|
| Normal saline | Drug | Normal saline in a labeled syringe |
|
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D007905 | Lens Diseases |
| D005128 | Eye Diseases |
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |